Vancouver, British Columbia–(Newsfile Corp. – March 9, 2021) – NeonMind Biosciences Inc. (CSE: NEON) (OTC: NMDBF) (FSE: 6UF) (“NeonMind“) is pleased to announce that on March 4, 2020 NeonMind engaged Philippe Martin as a drug development consultant. Mr. Martin has 20 years of biotechnology and pharmaceutical industry experience developing and commercializing innovative therapies in the fields of…


Previous articleMindMed Announces C$19.5 Million Bought Deal Private Placement Offering
Next articleBetter Plant Appoints Branding Expert Perry Chua as Chief Creative Officer